In Vitro Activity of Neomycin, Streptomycin, Paromomycin and Apramycin against Carbapenem-Resistant Enterobacteriaceae Clinical Strains
We determined the in vitro susceptibility of four aminoglycosides, which are not of the 4,6-disubstituted deoxystreptamine (DOS) subclass against a collection of carbapenem-resistant Enterobacteriaceae (CRE). CRE clinical strains (n = 134) were collected from multiple hospitals in China and carried...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-11-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fmicb.2017.02275/full |
| _version_ | 1818479329065041920 |
|---|---|
| author | Ya Hu Ya Hu Lu Liu Lu Liu Xiaoxia Zhang Xiaoxia Zhang Yu Feng Yu Feng Zhiyong Zong Zhiyong Zong Zhiyong Zong Zhiyong Zong |
| author_facet | Ya Hu Ya Hu Lu Liu Lu Liu Xiaoxia Zhang Xiaoxia Zhang Yu Feng Yu Feng Zhiyong Zong Zhiyong Zong Zhiyong Zong Zhiyong Zong |
| author_sort | Ya Hu |
| collection | DOAJ |
| description | We determined the in vitro susceptibility of four aminoglycosides, which are not of the 4,6-disubstituted deoxystreptamine (DOS) subclass against a collection of carbapenem-resistant Enterobacteriaceae (CRE). CRE clinical strains (n = 134) were collected from multiple hospitals in China and carried blaNDM (blaNDM−1, blaNDM−5 or blaNDM−7; n = 66), blaKPC−2 (n = 62) or blaIMP−4 (n = 7; including one carrying blaNDM−1 and blaIMP−4). MICs of neomycin, paromomycin, streptomycin and apramycin as well as three 4,6-disubstituted DOS aminoglycosides (amikacin, gentamicin and tobramycin) were determined using the broth microdilution with breakpoints defined by the Clinical Laboratory Standards Institute (for amikacin, gentamicin and tobramycin), US Food and Drug Administration (streptomycin), the National Antimicrobial Resistance Monitoring System (apramycin) or la Société Française de Microbiologie (neomycin and paromomycin). Apramycin-resistant strains were subjected to whole genome sequencing using Illumina X10 platform. Among CRE strains, 65.7, 64.9, 79.1, and 95.5% were susceptible to neomycin (MIC50/MIC90, 8/256 μg/ml), paromomycin (4/>256 μg/ml), streptomycin (16/256 μg/ml) and apramycin (4/8 μg/ml), respectively, while only 55.2, 28.4, and 35.1% were susceptible to amikacin (32/>256 μg/ml), gentamicin (128/>256 μg/ml) and tobramycin (64/>256 μg/ml), respectively. Six CRE strains including five Escherichia coli of different sequence types and one Klebsiella pneumoniae were resistant to apramycin and the apramycin-resistant gene aac(3)-IVa was detected in all of these strains. In conclusion, neomycin, paromomycin, streptomycin and apramycin retain activity against most CRE strains. Although none of these non-4,6-disubstituted DOS aminoglycosides are suitable for intravenous use in human at present, these agents warrant further investigations to be used against CRE infections. |
| first_indexed | 2024-12-10T11:09:09Z |
| format | Article |
| id | doaj.art-da2e9755e65148149ca511d218805ceb |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-12-10T11:09:09Z |
| publishDate | 2017-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-da2e9755e65148149ca511d218805ceb2022-12-22T01:51:29ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2017-11-01810.3389/fmicb.2017.02275311046In Vitro Activity of Neomycin, Streptomycin, Paromomycin and Apramycin against Carbapenem-Resistant Enterobacteriaceae Clinical StrainsYa Hu0Ya Hu1Lu Liu2Lu Liu3Xiaoxia Zhang4Xiaoxia Zhang5Yu Feng6Yu Feng7Zhiyong Zong8Zhiyong Zong9Zhiyong Zong10Zhiyong Zong11Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Infectious Diseases, State Key Laboratory of Biotherapy, Chengdu, ChinaCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Infectious Diseases, State Key Laboratory of Biotherapy, Chengdu, ChinaCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Infectious Diseases, State Key Laboratory of Biotherapy, Chengdu, ChinaCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Infectious Diseases, State Key Laboratory of Biotherapy, Chengdu, ChinaCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Infectious Diseases, State Key Laboratory of Biotherapy, Chengdu, ChinaDepartment of Infection Control, West China Hospital, Sichuan University, Chengdu, ChinaCenter for Pathogen Research, West China Hospital, Sichuan University, Chengdu, ChinaWe determined the in vitro susceptibility of four aminoglycosides, which are not of the 4,6-disubstituted deoxystreptamine (DOS) subclass against a collection of carbapenem-resistant Enterobacteriaceae (CRE). CRE clinical strains (n = 134) were collected from multiple hospitals in China and carried blaNDM (blaNDM−1, blaNDM−5 or blaNDM−7; n = 66), blaKPC−2 (n = 62) or blaIMP−4 (n = 7; including one carrying blaNDM−1 and blaIMP−4). MICs of neomycin, paromomycin, streptomycin and apramycin as well as three 4,6-disubstituted DOS aminoglycosides (amikacin, gentamicin and tobramycin) were determined using the broth microdilution with breakpoints defined by the Clinical Laboratory Standards Institute (for amikacin, gentamicin and tobramycin), US Food and Drug Administration (streptomycin), the National Antimicrobial Resistance Monitoring System (apramycin) or la Société Française de Microbiologie (neomycin and paromomycin). Apramycin-resistant strains were subjected to whole genome sequencing using Illumina X10 platform. Among CRE strains, 65.7, 64.9, 79.1, and 95.5% were susceptible to neomycin (MIC50/MIC90, 8/256 μg/ml), paromomycin (4/>256 μg/ml), streptomycin (16/256 μg/ml) and apramycin (4/8 μg/ml), respectively, while only 55.2, 28.4, and 35.1% were susceptible to amikacin (32/>256 μg/ml), gentamicin (128/>256 μg/ml) and tobramycin (64/>256 μg/ml), respectively. Six CRE strains including five Escherichia coli of different sequence types and one Klebsiella pneumoniae were resistant to apramycin and the apramycin-resistant gene aac(3)-IVa was detected in all of these strains. In conclusion, neomycin, paromomycin, streptomycin and apramycin retain activity against most CRE strains. Although none of these non-4,6-disubstituted DOS aminoglycosides are suitable for intravenous use in human at present, these agents warrant further investigations to be used against CRE infections.http://journal.frontiersin.org/article/10.3389/fmicb.2017.02275/fullcarbapenemaseaminoglycosidesapramycinstreptomycinneomycinparomomycin |
| spellingShingle | Ya Hu Ya Hu Lu Liu Lu Liu Xiaoxia Zhang Xiaoxia Zhang Yu Feng Yu Feng Zhiyong Zong Zhiyong Zong Zhiyong Zong Zhiyong Zong In Vitro Activity of Neomycin, Streptomycin, Paromomycin and Apramycin against Carbapenem-Resistant Enterobacteriaceae Clinical Strains Frontiers in Microbiology carbapenemase aminoglycosides apramycin streptomycin neomycin paromomycin |
| title | In Vitro Activity of Neomycin, Streptomycin, Paromomycin and Apramycin against Carbapenem-Resistant Enterobacteriaceae Clinical Strains |
| title_full | In Vitro Activity of Neomycin, Streptomycin, Paromomycin and Apramycin against Carbapenem-Resistant Enterobacteriaceae Clinical Strains |
| title_fullStr | In Vitro Activity of Neomycin, Streptomycin, Paromomycin and Apramycin against Carbapenem-Resistant Enterobacteriaceae Clinical Strains |
| title_full_unstemmed | In Vitro Activity of Neomycin, Streptomycin, Paromomycin and Apramycin against Carbapenem-Resistant Enterobacteriaceae Clinical Strains |
| title_short | In Vitro Activity of Neomycin, Streptomycin, Paromomycin and Apramycin against Carbapenem-Resistant Enterobacteriaceae Clinical Strains |
| title_sort | in vitro activity of neomycin streptomycin paromomycin and apramycin against carbapenem resistant enterobacteriaceae clinical strains |
| topic | carbapenemase aminoglycosides apramycin streptomycin neomycin paromomycin |
| url | http://journal.frontiersin.org/article/10.3389/fmicb.2017.02275/full |
| work_keys_str_mv | AT yahu invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT yahu invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT luliu invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT luliu invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT xiaoxiazhang invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT xiaoxiazhang invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT yufeng invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT yufeng invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT zhiyongzong invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT zhiyongzong invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT zhiyongzong invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains AT zhiyongzong invitroactivityofneomycinstreptomycinparomomycinandapramycinagainstcarbapenemresistantenterobacteriaceaeclinicalstrains |